company background image
IDRS.F logo

Idorsia OTCPK:IDRS.F Stock Report

Last Price

US$2.64

Market Cap

US$507.2m

7D

32.7%

1Y

-76.1%

Updated

27 Mar, 2024

Data

Company Financials +

IDRS.F Stock Overview

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.

IDRS.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Idorsia Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Idorsia
Historical stock prices
Current Share PriceCHF2.64
52 Week HighCHF11.00
52 Week LowCHF1.40
Beta0.80
1 Month Change60.00%
3 Month Change3.53%
1 Year Change-76.11%
3 Year Change-90.49%
5 Year Change-85.77%
Change since IPO-85.33%

Recent News & Updates

Recent updates

Shareholder Returns

IDRS.FUS BiotechsUS Market
7D32.7%0.9%0.4%
1Y-76.1%10.3%28.8%

Return vs Industry: IDRS.F underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: IDRS.F underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is IDRS.F's price volatile compared to industry and market?
IDRS.F volatility
IDRS.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: IDRS.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine IDRS.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aJean-Paul Clozelhttps://www.idorsia.com

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia.

Idorsia Ltd Fundamentals Summary

How do Idorsia's earnings and revenue compare to its market cap?
IDRS.F fundamental statistics
Market capUS$507.17m
Earnings (TTM)-US$413.05m
Revenue (TTM)US$203.94m

2.5x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IDRS.F income statement (TTM)
RevenueCHF184.69m
Cost of RevenueCHF349.11m
Gross Profit-CHF164.42m
Other ExpensesCHF209.63m
Earnings-CHF374.06m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)-2.09
Gross Margin-89.03%
Net Profit Margin-202.54%
Debt/Equity Ratio-136.1%

How did IDRS.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.